CN101022825B - 预防或治疗阿尔茨海默病的联合疗法及其试剂盒 - Google Patents

预防或治疗阿尔茨海默病的联合疗法及其试剂盒 Download PDF

Info

Publication number
CN101022825B
CN101022825B CN200580023830.5A CN200580023830A CN101022825B CN 101022825 B CN101022825 B CN 101022825B CN 200580023830 A CN200580023830 A CN 200580023830A CN 101022825 B CN101022825 B CN 101022825B
Authority
CN
China
Prior art keywords
app
binding
amyloid
beta
apheresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200580023830.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN101022825A (zh
Inventor
弗兰克·马特纳
沃尔特·施尔特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris Forschungs und Entwicklungs GmbH
Original Assignee
Affiris Forschungs und Entwicklungs GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Forschungs und Entwicklungs GmbH filed Critical Affiris Forschungs und Entwicklungs GmbH
Publication of CN101022825A publication Critical patent/CN101022825A/zh
Application granted granted Critical
Publication of CN101022825B publication Critical patent/CN101022825B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)
CN200580023830.5A 2004-07-13 2005-07-06 预防或治疗阿尔茨海默病的联合疗法及其试剂盒 Expired - Fee Related CN101022825B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ATA1185/2004 2004-07-13
AT0118504A AT500483B1 (de) 2004-07-13 2004-07-13 Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
PCT/EP2005/053224 WO2006005706A2 (de) 2004-07-13 2005-07-06 Kombinationstherapie zur vorbeugung oder behandlung der alzheimer´schen erkrankung sowie kit hierfür

Publications (2)

Publication Number Publication Date
CN101022825A CN101022825A (zh) 2007-08-22
CN101022825B true CN101022825B (zh) 2015-02-04

Family

ID=35115768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200580023830.5A Expired - Fee Related CN101022825B (zh) 2004-07-13 2005-07-06 预防或治疗阿尔茨海默病的联合疗法及其试剂盒

Country Status (14)

Country Link
US (2) US7935348B2 (enExample)
EP (1) EP1765388B8 (enExample)
JP (2) JP5642333B2 (enExample)
KR (1) KR101158600B1 (enExample)
CN (1) CN101022825B (enExample)
AT (1) AT500483B1 (enExample)
AU (1) AU2005261687B8 (enExample)
CA (1) CA2577332C (enExample)
DK (1) DK1765388T3 (enExample)
ES (1) ES2414872T3 (enExample)
PL (1) PL1765388T3 (enExample)
PT (1) PT1765388E (enExample)
TW (1) TW200602072A (enExample)
WO (1) WO2006005706A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008080045A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Dr6 antibodies inhibiting the binding of dr6 to app, and uses thereof in treating neurological disorders
WO2008104386A2 (en) * 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2226081A4 (en) 2007-10-25 2011-10-12 Univ Kagoshima PEPTIDE VACCINE WITH A MIMIC MOLECULE OF AMYLOID PEPTIDE
ES2332846B1 (es) 2007-10-26 2010-07-08 Grifols, S.A. Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos.
AT506820B1 (de) * 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
EP2320987A1 (en) * 2008-07-29 2011-05-18 Medtronic, Inc. Apheresis of a target molecule from cerebrospinal fluid
HUE027027T2 (en) * 2008-11-13 2016-08-29 Modgene Llc Reduction of amyloid beta load in non-brain tissue
CN104274875A (zh) 2008-12-22 2015-01-14 学校法人藤田学园 Aβ 除去材料、Aβ 除去器和Aβ 除去系统
US20110033463A1 (en) * 2009-08-06 2011-02-10 Medtronic, Inc. Apheresis, administration of agent, or combination thereof
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
JP5843345B2 (ja) 2010-07-08 2016-01-13 旭化成メディカル株式会社 β−アミロイド除去システム
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
DK2579042T3 (da) 2011-10-04 2014-07-21 Affiris Ag Fremgangsmåde til at påvise Aß-specifikke antistoffer i en biologisk prøve
MX352749B (es) 2011-11-01 2017-12-06 Modgene Llc Composiciones y metodos para la reduccion de la carga amiloide-beta.
CN110133298A (zh) * 2012-03-18 2019-08-16 株式会社资生堂 疾病样品分析装置、分析系统及分析方法
DE102012108598A1 (de) * 2012-09-14 2014-04-10 Forschungszentrum Jülich GmbH Neue, von D3 abgeleitete D-enantiomere Peptide und deren Verwendung
JP2015518474A (ja) * 2012-04-05 2015-07-02 フォルシュングスツェントルム ユーリッヒ ゲゼルシャフト ミット ベシュレンクテル ハフツングＦｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ Ｊｕｅｌｉｃｈ ＧｍｂＨ 血液、血液生産物及び器官を処置する方法
CN104380111B (zh) 2012-04-05 2017-08-29 于利希研究中心有限公司 包含多价结合淀粉样β蛋白的D‑肽的聚合物及其应用
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
CN106466298A (zh) * 2015-08-14 2017-03-01 上海交通大学医学院 一种单唾液酸四己糖神经节苷脂修饰的重组脂蛋白及其应用
CN109414482A (zh) * 2016-05-12 2019-03-01 俄亥俄州创新基金会 用于治疗神经退行性疾病的肽和方法
EP3655001A4 (en) * 2017-07-17 2021-04-28 Spark Therapeutics, Inc. Apheresis methods and uses
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CN115957324A (zh) * 2021-10-12 2023-04-14 首都医科大学宣武医院 外周CLU作为靶点在降低脑Aβ中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476715A (en) 1989-10-03 1995-12-19 Fresenius Ag Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits
JP3161604B2 (ja) 1994-05-13 2001-04-25 プラズマセレクト ゲーエムベーハー テテロウ 血液中の物質を結合してそれを除去するためのタンパク質を結合させた、無菌かつ発熱物質を含有しないカラム
EP0886085B1 (en) 1997-06-18 2002-04-03 Morse Tec Europe S.p.A. Sprocket wheel with improved tooth profile for greater silentness
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6551266B1 (en) 1998-12-29 2003-04-22 Occulogix Corporation Rheological treatment methods and related apheresis systems
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US20050227941A1 (en) * 2001-12-17 2005-10-13 Karen Duff Sequestration of ass in the periphery in the absence of immunomodulating agent as a therapeutic approach for the treatment or prevention of beta-amyloid related diseases
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
PL378571A1 (pl) * 2003-02-01 2006-05-02 Neuralab Limited Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20050158306A1 (en) * 2004-01-16 2005-07-21 Halikas James A. Treatment for neuro-degenerative disease by a blood cleansing system using monoclonal antibodies
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT500835B1 (de) * 2004-09-13 2007-12-15 Affiris Forschungs & Entwicklungs Gmbh Cholinestertransport-protein-mimotop als atherosklerose-medikament

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000719A2 (en) * 2001-06-20 2003-01-03 Ramot At Tel Aviv University Ltd. Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
WO2004013172A2 (en) * 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
WO2004056318A2 (en) * 2002-12-19 2004-07-08 New York University Method for treating amyloid disease

Also Published As

Publication number Publication date
KR101158600B1 (ko) 2012-07-09
US7935348B2 (en) 2011-05-03
DK1765388T3 (da) 2013-07-22
AT500483B1 (de) 2006-01-15
KR20070036158A (ko) 2007-04-02
CA2577332A1 (en) 2006-01-19
JP2008506665A (ja) 2008-03-06
TWI350173B (enExample) 2011-10-11
JP5642333B2 (ja) 2014-12-17
JP2013116903A (ja) 2013-06-13
TW200602072A (en) 2006-01-16
AU2005261687B8 (en) 2011-07-21
AU2005261687B2 (en) 2011-02-17
ES2414872T3 (es) 2013-07-23
EP1765388B1 (de) 2013-04-17
US20110201987A1 (en) 2011-08-18
CA2577332C (en) 2014-12-09
EP1765388B8 (de) 2013-05-29
HK1103354A1 (en) 2007-12-21
PL1765388T3 (pl) 2013-09-30
AT500483A4 (de) 2006-01-15
CN101022825A (zh) 2007-08-22
PT1765388E (pt) 2013-05-24
US20080051690A1 (en) 2008-02-28
AU2005261687A1 (en) 2006-01-19
WO2006005706A3 (de) 2006-07-20
WO2006005706A8 (de) 2006-11-16
WO2006005706A2 (de) 2006-01-19
EP1765388A2 (de) 2007-03-28
ES2414872T8 (es) 2014-11-06

Similar Documents

Publication Publication Date Title
CN101022825B (zh) 预防或治疗阿尔茨海默病的联合疗法及其试剂盒
Winblad et al. Active immunotherapy options for Alzheimer’s disease
US11952406B2 (en) Multi-epitope vaccine for the treatment of Alzheimer's disease
EA008762B1 (ru) АНАЛОГ АУТОЛОГИЧНОГО Аβ ИЛИ АРР ЖИВОТНОГО И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
KR20230080397A (ko) 알츠하이머 질환을 치료하기 위한 멀티에피토프 백신
KR20230087495A (ko) 알츠하이머 질환을 치료하기 위한 β-아밀로이드 백신
KR20230087499A (ko) 알츠하이머 질환 치료용 멀티에피토프 백신
CN1867365A (zh) 分离性输血－设备
US20230302127A1 (en) Tau vaccine for the treatment of alzheimer's disease
KR102460465B1 (ko) 알츠하이머병（ａｄ）의 치료 및 예방
KR102506460B1 (ko) 알츠하이머병（ａｄ）의 치료 및 예방
HK1103354B (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
Carrera et al. Novel immunotherapeutic procedures for prevention of Alzheimer’s disease
KR102388363B1 (ko) 알츠하이머병（ａｄ）의 치료 및 예방
Triplett et al. Active immunization targeting amyloid β for the treatment of Alzheimer’s disease
US20250134973A1 (en) Liposomes Containing Phosphorylated Tau Peptides for Inducing Sustained Immune Responses
WO2006097416A1 (en) Compounds for use in the prevention and treatment of alzheimer's disease
Winblad et al. Active immunotherapy options for Alzheimer’s

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1103354

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1103354

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150204

Termination date: 20170706

CF01 Termination of patent right due to non-payment of annual fee